ACTR-09. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS

BACKGROUND: Inhibition of mTORC1 signaling has been shown to diminish growth of NF2 deficient tumors in preclinical studies, and clinical data suggest that everolimus, an orally administered mTORC1 inhibitor, may slow tumor progression in a subset of adult and pediatric NF2 patients with VS. To asse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Karajannis, Matthias, Goldberg, Judith, Thomas Roland, J, Sen, Chandranath, Placantonakis, Dimitris, Golfinos, John, Allen, Jeffrey, Dunbar, Erin, Plotkin, Scott, Akshintala, Srivandana, Schneider, Robert, Deng, Jingjing, Neubert, Thomas A, Giancotti, Filippo, Zagzag, David, O Blakeley, Jaishri
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847850/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados